Detalles de la búsqueda
1.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081335
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33725432
3.
Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C.
J Infect Dis
; 227(5): 610-621, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36130327
4.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis
; 76(2): 201-209, 2023 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36196614
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691324
6.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet
; 399(10324): 521-529, 2022 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35074136
7.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883053
8.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729167
9.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480858
10.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306989
11.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33220855
12.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33798499
13.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34863358
14.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370971
15.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617777
16.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702298
17.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger in muscarinic receptor-induced contraction of guinea pig trachea.
J Biol Chem
; 288(16): 10986-93, 2013 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-23467410
18.
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Lancet Microbe
; 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38878794
19.
Nicotinic acid adenine dinucleotide phosphate regulates skeletal muscle differentiation via action at two-pore channels.
Proc Natl Acad Sci U S A
; 107(46): 19927-32, 2010 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21041635
20.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Hum Vaccin Immunother
; 19(2): 2233400, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37438960